Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt official

07/04/2021 | 11:55pm EDT

SEOUL, July 5 (Reuters) - South Korea is in talks with mRNA vaccine makers including Pfizer and Moderna to produce COVID-19 shots in the country and is ready to offer the capacity to make up to 1 billion doses immediately, a senior government official said.

The plan, if agreed, would help ease tight global supply of COVID-19 vaccines, particularly in Asia which lags North America and Europe in vaccine rollouts, and put South Korea a step closer to its ambition to become a major vaccine manufacturing centre.

South Korea already has deals to locally produce three coronavirus vaccines developed by AstraZeneca/Oxford University, Novavax, and Russia. It also has a vaccine bottling and packaging deal with Moderna.

"We've been holding frequent talks with big pharmaceutical companies to produce mRNA vaccines," Lee Kang-ho, director general for the global vaccine hub committee under South Korea's health ministry, told Reuters in an interview.

"There are only a few mRNA vaccine developers - Pfizer, Moderna, CureVac and BioNTech. Thus there's a limit to how much they can produce to meet global demand... South Korea is keen to help by offering its facilities and skilled human resources," Lee said.

It's not immediately clear how advanced these talks are and whether and when a deal will be agreed.

BioNTech declined to comment, Moderna and CureVac did not reply to Reuters' requests for comments.

A Pfizer spokesperson said the company is making efforts to enhance its COVID-19 vaccine supply chain but added "we do not have anything specific to announce at this time."

Lee declined to name local vaccine makers which have the capacity to produce mRNA vaccines immediately, but a government source said they include Hanmi Pharmaceuticals Co Ltd and Quratis Co Ltd.

Hanmi confirmed that it has a big capacity reserved for Sanofi's diabetes drug and it can be used for COVID-19 vaccine production as the Sanofi project has stalled.

Quratis, which makes a tuberculosis vaccine, said its new factory built last year can now be used for mRNA vaccine production. (Reporting by Sangmi Cha in Seoul; Additional reporting by Stephanie Nebehay in Geneva, Michael Erman in New York and Ludwig Burger in Frankfurt; Editing by Miyoung Kim and Raju Gopalakrishnan)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.81% 8326 Delayed Quote.10.09%
HANMI PHARM. CO., LTD. 0.50% 301000 End-of-day quote.-17.87%
HANMI SCIENCE CO., LTD. -0.57% 69700 End-of-day quote.-8.41%
MODERNA, INC. -2.41% 430.05 Delayed Quote.311.65%
NOVAVAX, INC. 0.11% 237.54 Delayed Quote.113.02%
SAMSUNG BIOLOGICS CO.,LTD. 1.86% 933000 End-of-day quote.12.95%
SANOFI 0.26% 81.74 Real-time Quote.3.62%
Latest news "Economy & Forex"
04:29aFTSE Tumbles on China, Inflation Worries
04:26aWILLIS TOWERS WATSON PUBLIC : Investment consultants advising $10 trln in assets launch climate initiative
04:26aOVHCloud CEO says premature to talk about company's valuation in IPO
04:26aEvergrande worries drag risk FX lower, dollar catches safety bid
04:22aEquinor wins permission to hike Troll, Oseberg gas exports, DN reports
04:22aChina wealth plans threaten European luxury stocks' post-COVID boom
04:20aWarning for increased risk of fire danger issued for Northern California counties
04:10aChina's August soybean imports from Brazil rise 10.9% y/y
04:03aAustralian trade min seeks French meeting, confident subs row won't derail EU talks
04:00aGSK : Ubs cuts target price to 1460p from 1540p
Latest news "Economy & Forex"